drugset / Trial / NCT03011177

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

NCT03011177

Phase 4 Completed 168 enrolled Handok Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

Timeline

Start
2017-01
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linagliptin Small molecule 5 mg
Subject Teneligliptin Small molecule 20 mg